echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > JAMA: Moderna's mRNA vaccine has fewer breakthrough infections, fewer hospitalizations than Pfizer

    JAMA: Moderna's mRNA vaccine has fewer breakthrough infections, fewer hospitalizations than Pfizer

    • Last Update: 2022-02-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    At the end of 2020, it took only one year for Pfizer/BioNTech and Moderna to develop a new crown mRNA vaccine, which was approved for marketing


    With the continuous emergence and large-scale spread of new mutants of the new coronavirus, the protective effect of the vaccines developed against the original strains began to decline, and some people who had received two doses of mRNA vaccines were still infected with the new coronavirus, which is the so-called " breakthrough ".


    breakthrough infection breakthrough infection

    On January 20, 2022, Rong Xu of Case Western Reserve University and others published a paper entitled: Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Research paper on Delta-Predominant Period


    Case Western Reserve University Rong XuJAMA JAMA Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period

    The paper compared breakthrough infections, hospitalizations, and deaths during the delta mutant epidemic between two mRNA vaccines from Pfizer/BioNTech and Moderna, respectively


    Comparing breakthrough infections, hospitalizations, and deaths during the delta mutant epidemic between the two mRNA vaccines from Pfizer/BioNTech and Moderna, respectively, compared with the Pfizer/BioNTech mRNA vaccine, breakthrough infections and hospitalizations in people vaccinated with Moderna Lower risk of breakthrough infection and hospitalization for Moderna vaccine recipients compared to Pfizer/BioNTech mRNA vaccine

    Rong Xu, who led the study, is a professor of bioinformatics at Case Western Reserve University School of Medicine and director of the Center for Artificial Intelligence Drug Discovery


    The statistics are based on a breakthrough infection of the new crown between July 2021 and November 2021, when Delta accounted for almost all cases


    Statistical results show that compared with Pfizer/BioNTech's mRNA vaccine, the monthly breakthrough infection rate of people vaccinated with Moderna's mRNA is lower.


    Compared with Pfizer/BioNTech's mRNA vaccine, people vaccinated with Moderna's mRNA had lower monthly breakthrough infections, for example, in November 2021, the breakthrough infection rate in the population vaccinated with Moderna's mRNA was 1.


    These data suggest that the two mRNA vaccines, despite their differences in preventing breakthrough infections, both have good protection against severe disease


    Although the two mRNA vaccines have differences in preventing breakthrough infections, both have good protection against severe severe cases

    With the rapid spread of Omicron, it is necessary to further evaluate the protective effect of the booster needle, and it is also necessary to develop a vaccine against Omicron


    Original source:

    Original source:

    Lindsey Wang, et al.


    Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant PeriodLeave

    a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.